← Eichor
Condition: Metastatic Basal Cell Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Basal Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Phase N/A · 8 location(s) · Maastricht University Medical Center · NCT05463757
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
NA · 1 location(s) · Alpha Tau Medical LTD. · NCT03889899
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05859074
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metasta
Phase 1/Phase 2 · 26 location(s) · National Cancer Institute (NCI) · NCT05896839
Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2 · 1 location(s) · Fudan University · NCT06683846
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Phase N/A · 4 location(s) · Vanderbilt University Medical Center · NCT00898638
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
NA · 1 location(s) · Alpha Tau Medical LTD. · NCT04534127
A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626
French National Database of Rare Dermatological Cancers
Phase N/A · 34 location(s) · University Hospital, Lille · NCT03210935
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cel
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT03521830
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
NA · 2 location(s) · Alpha Tau Medical LTD. · NCT04068155
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.